Abstract
Purpose – is to assess the effectiveness of combined intravitreal anti-VEGF injection with transscleral diode laser cyclophotocoagulation (TDLC) in the treatment of refractory neovascular glaucoma. Materials and methods The study included 20 patients (20 eye) diagnosed with refractory neovascular glaucoma in one eye. Among them, 14 (70%) developed the condition due to proliferative diabetic retinopathy, and 6 (30%) due to ischemic central retinal vein occlusion. All patients were divided into two groups. In the first group (I), TDLC was performed (10 patients, 10 eye), whereas in the second group (II), an intravitreal injection of Bevacizumab was administered 14 days prior to the procedure as part of a combined therapy (10 patients, 10 eye). Results In the I group, despite improvements in indicators, hyphema was detected in the anterior chamber of 8 out of 10 patients (80%), while two had hemophthalm (20%). In II group, stable improvements in all indicators were observed after 21 days; however, in the I group, one patient required a repeat procedure due to an increase in intraocular pressure to 32 mm Hg. Conclusion The preoperative use of anti-VEGF agents, including Bevacizumab, before TDLC is a rationally justified method and is recommended in the treatment of neovascular glaucoma. Key words: refractory neovascular glaucoma, anti-VEGF injection, transscleral diode laser cyclophotocoagulation
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call